이 누리집은 대한민국 공식 전자정부 누리집입니다.

한상넷

비즈니스 정보

Biz News Korea(Eng)

Biogen gets approval of therapy for spinal muscular atrophy in Korea

Collected: 2018.01.08

Distributed: 2018.01.09

Source: Go Direct

Biogen Korea, the Korean unit of American multinational biotech company Biogen Inc., announced on Monday it has received marketing approval from the Ministry of Food and Drug Safety for Spinraza, a drug used in treating spinal muscular atrophy (SMA), a rare neuromuscular disorder.

Spinraza is the first and only approved SMA drug and the company’s first prescription drug to be launched in Korea.

SMA is a genetic disease characterized by loss of motor neurons and progressive muscle wasting, often leading to early death.

Biogen Korea said Spinraza is the only treatment option for SMA patients and it will go all out to bring the benefits of the innovative product to local patients. To date, physical therapy has been used to relieve symptoms and delay the progression.

Biogen is a leading American biotech company with revenue of $11.44 billion in 2016. It landed in Korea last July and appointed its Korean head in November.

By Shin Chan-ok and Minu Kim

List

Previous: Seoul financial authorities probe banks on bitcoin asset services

Next: Hanmi Pharm tops list of number of clinical trials approved last year